• Flatiron Health Pioneers International Patient-Level Data Sharing for Oncology Research

    Mar 20 | Clinical Research News | Flatiron Health is breaking new ground in oncology research by enabling patient-level real-world data (RWD) sharing across four countries—U.S., UK, Germany, and Japan. Despite initial skepticism, researchers are now eager to access these harmonized electronic health record (EHR) datasets in a secure, cloud-based environment. More

  • AI Platform Aims to Translate Trial Results at the Point of Care

    Mar 18 | Clinical Research News | For medical oncologists, the clinical quandary in treating patients is whether a newly marketed agent or drug cocktail will work as well as it did for the average cancer patient in a landmark clinical trial. More

  • Navigating the Real-World: How to Better Utilize Real-World Evidence

    Mar 14 | Clinical Research News | Interest in Real-World Evidence (RWE) studies continues to grow. Data from ClinicalTrials.gov shows the number of RWE studies registered has increased dramatically since 2005, particularly in the last seven years. But what is RWE, how is it used in clinical trials and how can we work with Real-World Data (RWD) to produce RWE? More

  • Jumo Health Broadening its Health Equity Approach

    Mar 12 | Clinical Research News | Jumo Health launched a suite of services to drive health equity in clinical trials in 2023 via a collaboration with I Choose Life Foundation, a nonprofit dedicated to addressing health disparities in the African American community. It helped the company pilot its first community engagement event in the form of a workshop to train local business and faith leaders to serve as trusted messengers of information about clinical research and the point-of-care experience. More

  • Black Women with Breast Cancer Now Lead Champions of Clinical Trials

    Mar 11 | Clinical Research News | For Black women diagnosed with breast cancer, the grim reality is that they are 41% more likely to die of the disease than white women. African American women are disproportionately affected by triple negative breast cancer (TNBC), the most aggressive form of the disease, but that only partially explains the discrepancy in the mortality rate. More

  • The Scope of Things: Sharing Patient Insights, Absence of Pregnant Women in Clinical Trials, Boosting Cancer Vaccine Work, More

    Mar 06 | Clinical Research News | In this month’s episode of the Scope of Things, host Deborah Borfitz delivers the news on how an AI-powered trial screening tool outperformed human research staff, a strategy report on boosting cancer vaccine work, the issue of continued absence of pregnant women in clinical trials, and more. Plus, Rare Patient Voice founder and president Wes Michael also joins in to talk about how his company is connecting people undertaking research studies with participants eager to share their insights. More

  • AstraZeneca Scaling Up Use of Generative AI to Help Reach 2030 Ambitions

    Mar 04 | Clinical Research News | Generative artificial intelligence is being used by AstraZeneca to expedite its five-year ambitions to be an $80 billion company, deliver 20 new medicines, and be carbon negative. The initial value-driving activities include the creation of AI assistants to help with 3D location detection on CT scans and facilitate knowledge extraction for clinical documents as well as an intelligent protocol tool built in partnership with medical writers. More

  • Thermo Fisher Lupus Registry, Major Partnerships, Glaucoma Testing, More

    Feb 27 | Clinical Research News | Thermo Fisher Scientific launched the CorEvitas Systemic Lupus Erythematosus (SLE) Registry; MedTech Innovator announced new industry partners; Seonix Bio announced the US launch of SightScore for primary open-angle glaucoma; and more. More

  • Follow the Money: Rare Muscle Disease Treatment, Huntington’s Disease Trial, More

    Feb 26 | Clinical Research News | Abcuro is advancing to a Phase II/III trial to treat a rare, chronic inflammatory muscle disease called inclusion body myositis; Atalanta Therapeutics plans to start Phase I clinical trials of the company’s RNAi therapies for a genetic form of childhood epilepsy and for Huntington’s disease; and more. More

  • Regulators Support ‘Pragmatism’ in Clinical Trials

    Feb 25 | Clinical Research News | A panel of experts from inside several major pharma companies discussed regulatory initiatives around pragmatic trials in depth at the recent Summit for Clinical Trial Ops Executives (SCOPE). Henry Wei, M.D., head of development innovation at Regeneron; Gracy Crane, international regulatory policy lead for real-world data at Roche Products Limited; Melodi J. McNeil, director of regulatory policy and intelligence at AbbVie; Stephanie Derbyshire, clinical operations portfolio leader at Roche; and Kevin Bugin, associate vice president of global regulatory policy and intelligence at Amgen were all part of the panel. More
View more articles
 
DXX-Industry-spotlight
SOT

The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News Senior writer Deborah Borfitz welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.

Read More